<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104229">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01942161</url>
  </required_header>
  <id_info>
    <org_study_id>031-09-003</org_study_id>
    <secondary_id>JapicCTI-101146</secondary_id>
    <nct_id>NCT01942161</nct_id>
  </id_info>
  <brief_title>A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Dose-comparison Study of Three Different Doses of Aripiprazole (2 mg/Day, 6-12 mg/Day, 24-30 mg/Day) Orally Administered Over 6 Weeks in Pediatric Patients (Aged 13-17 Years) With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate the efficacy and safety of three different
      doses of aripiprazole (2 mg/day, 6-12 mg/day, 24-30 mg/day) orally administered over a
      period of 6 weeks in pediatric patients (aged 13-17 years) with schizophrenia
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS) total sore</measure>
    <time_frame>baseline, Day 43</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from baseline to final evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS score</measure>
    <time_frame>Screening, Day1, Day8, Day15, Day22, Day29, Day43</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>Day1, Day8, Day15, Day22, Day29, Day43</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's Global Assessment Scale (CGAS)</measure>
    <time_frame>Day1, day43</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to Day 43</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Screening, Day43</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Low (2 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the 2 mg/day group will be administered 2 mg once daily for 6 weeks (42 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid (6 - 12 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the 6-12 mg/day group will be administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days.  From Day 15 onwards, the dose may be increased to 12 mg in accordance with the criteria below.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High (24 - 30 mg/day)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the 24-30 mg/day group will be administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg in accordance with the criteria below.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole Low (2 mg/day)</intervention_name>
    <description>administered 2 mg once daily for 6 weeks</description>
    <arm_group_label>Low (2 mg/day)</arm_group_label>
    <other_name>Aripiprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole Mid (6 - 12 mg/day)</intervention_name>
    <description>administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days.  From Day 15 onwards, the dose may be increased to 12 mg</description>
    <arm_group_label>Mid (6 - 12 mg/day)</arm_group_label>
    <other_name>Aripiprazole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aripiprazole High (24 - 30 mg/day)</intervention_name>
    <description>administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg</description>
    <arm_group_label>High (24 - 30 mg/day)</arm_group_label>
    <other_name>Aripiprazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of schizophrenia (295.30, 295.10, 295.20, 295.90, 295.60),
             according to DSM-Ⅳ-TR (M.I.N.I.KID will be used as backup)

          -  Male and female patients aged 13-17 years (between IC and end of dosing)

          -  Patients with a PANSS score of 70 or more [both at start of dosing (Day 1 and at
             baseline

          -  Patients who, in addition to their legal guardian, provide written informed consent,
             having understood the details of this study

          -  Inpatient or outpatient status

        Exclusion Criteria:

          -  Patients who have a diagnosis of any other disease except schizophrenia, according to
             DSM-IV-TR

          -  Patients who have been compulsorily admitted to hospital

          -  Patients with mental retardation

          -  Patients with thyroid disorder

          -  Patients who have a history of receiving treatment with clozapine, or who have
             received sufficient doses of two or more kinds of antipsychotic drug for more than
             four weeks but failed to respond to this treatment

          -  Patients who have received a prohibited concomitant medication or therapy listed in
             table 6.4-1 after the start of the prohibited concomitant medication timeframe [to be
             confirmed at start of dosing (Day 1) and at baseline].

          -  Patients who have a history of receiving treatment with aripiprazole

          -  Patients who fall under a contraindication listed in the ABILIFY package insert

          -  Patients with a serious hepatic, renal, cardiac or hematopoietic disorder

          -  Patients with a history or a complication of organic brain disorder or convulsive
             disorder such as epilepsy

          -  Patients with diabetes. and patients who fall under any of the following:

        fasting blood glucose level ≧126 mg/ｄL, non-fasting blood glucose level ≧200 mg/dL,
        HbA1c≧6.5%

          -  Patients with a history or a complication of suicide attempt, suicidal thought or
             self-harm

          -  Patients with a score of ≧2(mild) on PART1 evaluation of CGI-SS

          -  Patients with a history or a complication of malignant syndrome, tardive dyskinesia
             or paralytic ileus

          -  Patients in a state of physical exhaustion accompanied by such conditions as
             dehydration or malnutrition

          -  Patients with a history or a complication of water intoxication

          -  Patients with Parkinson's disease

          -  Pregnant women, parturient women, nursing women, women of childbearing potential who
             wish to become pregnant during this trial.  However, women of childbearing potential
             who are practicing an appropriate method of contraception and have a negative
             pregnancy test result are eligible for inclusion in this study.

          -  Patients who have a diagnosis of a substance-related disorder according to DSM-Ⅳ-TR
             within the past 3 months

          -  Patients with a positive drug screen (urine) result

          -  Study enrollment is otherwise judged to be inappropriate by the Investigator or
             Subinvestigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyoji Imaoka, Mr</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chubu Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 12, 2013</lastchanged_date>
  <firstreceived_date>September 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schyzophrenia, pediatric patients</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
